NPM1 activates metabolic changes by inhibiting FBP1 while promoting the tumorigenicity of pancreatic cancer cells

Yi Zhu; Minmin Shi; Hao Chen; Jiangning Gu; Jiaqiang Zhang; Baiyong Shen; Xiaxing Deng; Junjie Xie; Xi Zhan; Chenghong Peng

doi:10.18632/oncotarget.4167

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

NPM1 activates metabolic changes by inhibiting FBP1 while promoting the tumorigenicity of pancreatic cancer cells

Yi Zhu _, Minmin Shi, Hao Chen, Jiangning Gu, Jiaqiang Zhang, Baiyong Shen, Xiaxing Deng, Junjie Xie, Xi Zhan and Chenghong Peng

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:21443-21451. https://doi.org/10.18632/oncotarget.4167

Metrics: PDF 2540 views | HTML 4128 views | ?

Abstract

Yi Zhu1,*, Minmin Shi2,*, Hao Chen1,2, Jiangning Gu1, Jiaqiang Zhang1, Baiyong Shen1,2, Xiaxing Deng1,2, Junjie Xie1, Xi Zhan1,2, Chenghong Peng1,2

1Department of Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P.R. China

2Research Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P.R. China

*These authors have contributed equally to this work

Correspondence to:

Hao Chen, e-mail: [email protected]

Chenghong Peng, e-mail: [email protected]

Keywords: pancreatic ductal adenocarcinoma, NPM1, FBP1, warburg effect

Received: March 30, 2015 Accepted: May 23, 2015 Published: June 05, 2015

ABSTRACT

The nucleophosmin (NPM1) activates cancer development and progression in many malignant tumors. However, the regulatory role and underlying mechanisms of NPM1 in pancreatic cancer are unknown. In this study, we showed that NPM1 was up-regulated in PDAC, which indicated a poor prognosis. We also identified NPM1 could stimulate aerobic glycolysis and repress fructose-1, 6-bisphosphatase 1 (FBP1) in pancreatic cancer cells. Restoring FBP1 expression partially reversed the tumor-promoting effects of NPM1, while the loss of FBP1 in PDAC tissues was indicative of a poorer prognosis. In sum, NPM1 promotes aerobic glycolysis and tumor progression in patients with pancreatic cancer by inhibiting FBP1.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4167

Publication Alerts

Research Papers:

NPM1 activates metabolic changes by inhibiting FBP1 while promoting the tumorigenicity of pancreatic cancer cells

Abstract